BergenBio Fundamentale Forhold (BGBIO)

[TekBot]

BerGenBio ASA - Commencement of the first exercise period for warrants issued in connection with rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED

STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
…

Vis børsmeldingen

PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen, 15 November 2023 - Reference is made to the stock exchange announcement
from BerGenBio ASA (the “Company”) dated 14 June 2023 regarding the final
results of the rights issue of 2,500,000,000 new shares in the Company (the
“Offer Shares”), raising gross proceeds of NOK 250 million (the “Rights Issue”),
and the allocation and issuance to subscribers in the Rights Issue of one
warrant for every two Offer Shares allocated to them and paid by them in the
Rights Issue (the “Warrants”).

As announced on 14 June 2023, the Company has issued 1,249,999,617 Warrants. The
Warrants are listed and tradable on the Oslo Stock Exchange from 23 June 2023 to
16:30 hours (CEST) on 8 April 2024 under the ticker code “BGBIS”. Each Warrant
gives the holder a right to subscribe for one new share in the Company at an
exercise price per share as described below during two exercise periods (such
new shares jointly the “New Shares”).

The first exercise period for the Warrants will commence today, on 15 November
2023.

Carnegie AS and Arctic Securities AS are acting as managers in connection with
exercise of Warrants (jointly the “Managers”).

Exercise periods

The Warrants may be exercised during the following two exercise periods: (i)
from 15 November 2023 to 28 November 2023 at 16:30 hours (CET), or (ii) from 1
April 2024 to 15 April 2024 at 16:30 hours (CEST). Any Warrants to be exercised
in the first exercise period will have to be registered on the VPS account of
the subscriber on 28 November 2023. Provided that a purchase of Warrants is made
with ordinary T+2 settlement, Warrants purchased up to and including 24 November
2023 may be exercised in the first exercise period, whereas Warrants purchased
from and including 25 November 2023, may not be exercised in the first exercise
period.

Warrants that are not exercised before the expiry of the second exercise period
on 15 April 2024 at 16:30 (CEST) or not sold before 16:30 (CEST) on 8 April 2024
will have no value and will lapse without compensation to the holder.

Holders of Warrants who do not exercise their Warrants to subscribe for New
Shares will experience a dilution of their shareholding in the Company. See
Section 6.29 “Dilution” in the Company’s prospectus dated 26 May 2023 (the
“Prospectus”) for a further description of such dilutive effect.

The Prospectus is, subject to applicable local securities laws, available at the
websites of the Company (www.bergenbio.com/investors), Carnegie AS
(www.carnegie.no/ongoing-prospectuses-and-offerings/) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Number of New Shares and exercise price per New Share

Each Warrant gives the holder a right to subscribe for one New Share at an
exercise price per share equal to the volume-weighted average price (VWAP) of
the Company’s shares on the Oslo Stock Exchange in the three last trading days
prior to the first date on which the holder can exercise the Warrant in each
exercise period less 30%, but in any event (i) not lower than the nominal value
(NOK 0.10) and (ii) not exceeding the subscription price in the Rights Issue
plus 30% (i.e. NOK 0.13).

Based on the criteria above, the exercise price per New Share in the first
exercise period (15 November 2023 to 28 November 2023) is NOK 0.13.

Exercise procedure

Warrants are exercised through the submission of a duly completed exercise form
for the Warrants (the “Exercise Form”) to one of the Managers at the address or
email address set out in the Prospectus and the Exercise Form, or electronically
through the VPS online subscription system, during one of the exercise periods
for the Warrants. The Exercise Form can be found at the websites of the Company
(www.bergenbio.com/investors ), Carnegie AS (www.carnegie.no/ongoing
-prospectuses-and-offerings/)and Arctic Securities AS
(www.arctic.com/secno/en/offerings). By completing and submitting an Exercise
Form, the holder of the relevant Warrants irrevocably undertakes to acquire a
number New Shares equal to the number of Warrants exercised at the relevant
exercise price.

The primary insiders of the Company holding Warrants have indicated that they
will exercise all of their respective Warrants in the first exercise period.

Payment for and delivery of New Shares

Notifications of allocated New Shares and the corresponding aggregate exercise
price to be paid by each subscriber are expected to be distributed in a letter
from the VPS after the end of the first exercise period, on or about 30 November
2023. Payment for the New Shares allocated to the subscriber after the end of
the First Exercise Period falls due on 5 December 2023 in accordance with the
payment procedures described in the Exercise Form.

Subject to timely payment of the exercise price for the New Shares on 5 December
2023, the Company expects that the share capital increase pertaining to the
exercise of Warrants will be registered with the Norwegian Register of Business
Enterprises on or about 6 December 2023 and that the New Shares will be
delivered to the VPS accounts of the subscribers to whom they are allocated on
or about 7 December 2023.

The New Shares may not be transferred or traded before they are fully paid and
the share capital increase pertaining to the exercise of Warrants has been
registered with the Norwegian Register of Business Enterprises.

A subscriber’s default in timely payment of the exercise price for the New
Shares subscribed by such subscriber will result in that the New Shares
subscribed will not be issued and the Warrants exercised will be forfeited and
will not give a right to subscribe New Shares.

Financial intermediaries

If Warrants are registered through a financial intermediary, the financial
intermediary will customarily give the holder details of the aggregate number of
Warrants which it is entitled to exercise. The relevant financial intermediary
will customarily supply each holder with this information in accordance with its
usual customer relations procedures. Holders of Warrants through a financial
intermediary should contact the financial intermediary if they have received no
information with respect to the Warrants.

Listing and commencement of trading in the New Shares

The New Shares issued upon exercise of Warrants will be listed on the Oslo Stock
Exchange under ISIN NO 001 0650013 and ticker code “BGBIO”. The New Shares will
be listed as soon as the New Shares are fully paid, the share capital increase
pertaining to the New Shares has been registered in the Norwegian Register of
Business Enterprises, the New Shares have been issued in the VPS, and the
Company has published a prospectus in relation to the listing of the New Shares
approved by the Norwegian Financial Supervisory Authority (the “NFSA”) (the
“Listing Prospectus”).

The New Shares will, if required, be placed on a separate ISIN pending
publication of the Listing Prospectus until they are listed. The Listing
Prospectus will be published on the Company’s web site once it has been approved
by the NFSA, which is expected to be on or about 7 December 2023.

The New Shares are expected to be tradable on the Oslo Stock Exchange from the
time the Company has published the Listing Prospectus approved by the NFSA.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

For information about the Warrants please contact one of the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is published in accordance with the requirements of the
Continuing Obligations.

Kilde

[TekBot]

BerGenBio ASA - Start av den første utøvelsesperioden for de frittstående tegningsrettene utstedt i forbindelse med fortrinnsrettsemisjonen

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED

STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
…

Vis børsmeldingen

PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen, 15. november 2023 - Det vises til børsmeldingen fra BerGenBio ASA
(“Selskapet”) datert 14. juni 2023 vedrørende det endelige resultatet av
fortrinnsrettsemisjonen av 2.500.000.000 nye aksjer I Selskapet
(“Tilbudsaksjene”), som reiste bruttoproveny på NOK 250 millioner
(“Fortrinnsrettsemisjonen”), og allokering og utstedelse til tegnerne i
Fortrinnsrettsemisjonen av en frittstående tegningsrett for hver andre
Tilbudsaksje allokert til, og betalt av, dem i Fortrinnsrettsemisjonen
(“Frittstående Tegningsretter”).

Som annonsert den 14. juni 2023, har Selskapet utstedt 1.249.999.617
Frittstående Tegningsretter. De Frittstående Tegningsrettene er noterte fra 23.
juni 2023 og kan handles på Oslo Børs frem til kl 16:30 (CEST) den 8. april 2024
under ticker-koden “BGBIS”. Hver Frittstående Tegningsrett gir innehaveren rett
til å tegne en ny aksje i Selskapet for en utøvelsespris pr aksje som beskrevet
nedenfor i løpet av to utøvelsesperioder (slike nye aksjer omtales samlet som
“Nye Aksjene”).

Den første utøvelsesperioden for de Frittstående Tegningsrettene starter i dag,
den 15. November 2023.

Carnegie AS og Arctic Securities AS er tilretteleggere i forbindelse med
utøvelse av Frittstående Tegningsretter (i fellesskap, “Tilretteleggerne”).

Utøvelsesperioder

De Frittstående Tegningsrettene kan utøves i løpet av de følgende to
utøvelsesperioder: (i) fra 15. november 2023 til 28. november 2023 kl. 16.30
(CET), eller (ii) fra 1. april 2024 til 15. april 2024 kl 16.30 (CEST). Enhver
Frittstående Tegningsrett som skal utøves i den første utøvelsesperioden må være
registrert på tegnerens VPS-konto den 28. november 2023. Forutsatt at et kjøp av
Frittstående Tegningsretter gjøres med ordinært T+2-oppgjør, kan Frittstående
Tegningsretter ervervet til og med 24. november 2023 utøves i den første
utøvelsesperioden, mens Frittstående Tegningsretter ervervet fra og med 25.
november, ikke kan utøves i den første utøvelsesperioden.

Frittstående Tegningsretter som ikke er utøvet før utløpet av den andre
utøvelsesperioden, den 15. april 2024 kl. 16.30 (CEST) eller ikke solgt før 8
April 2024 kl. 16.30 (CEST) vil ikke ha noen verdi og vil utløpe uten
kompensasjon til innehaveren.

Innehavere av Frittstående Tegningsretter som ikke utøver sine Frittstående
Tegningsretter til å tegne Nye Aksjer vil oppleve en utvanning av sitt eierskap
i Selskapet. Se punkt 6.29 “Dilution” i Selskapets prospekt datert 26. mai 2023
(“Prospektet”) for ytterligere beskrivelse av slik utvannende effekt.

Prospektet er, med forbehold for lokale verdipapirlover, tilgjengelig på
websidene til Selskapet (www.bergenbio.com/investors), Carnegie AS
(www.carnegie.no/ongoing-prospectuses-and-offerings/) og Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Antall Nye Aksjer og utøvelsespris pr Nye Aksje

Hver Frittstående Tegningsrett gir innehaveren en rett til å tegne en Ny Aksje
til en utøvelsespris tilsvarende den volumveide gjennomsnittsprisen (VWAP) på
Selskapets aksjer på Oslo Børs i de tre seneste handelsdagene forut for den
første dato hvor innehaveren kan utøve Frittstående Tegningsretter i hver
utøvelsesperiode minus 30%, men i alle tilfeller (i) ikke lavere enn pålydende
(NOK 0,10) og (ii) ikke over tegningskursen i Fortrinnsrettsemisjonen pluss 30%
(dvs. NOK 0,13).

Basert på kriteriene over, er utøvelsesprisen pr Nye Aksje i den første
utøvelsesperioden (15. november 2023 til 28. november 2023) NOK 0,13.

Utøvelsesprosedyre

Frittstående Tegningsretter utøves ved innsendelse av en korrekt utfylt
utøvelsesblankett (“Utøvelsesblanketten”) til en av Tilretteleggerne på adressen
eller e-postadressen angitt i Prospektet eller i Utøvelsesblanketten, eller
elektronisk gjennom VPS’ online tegningssystem i løpet av en av
utøvelsesperiodene for de Frittstående Tegningsrettene. Utøvelsesblanketten kan
finnes på nettsidene til Selskapet (www.bergenbio.com/investors), Carnegie AS
(www.carnegie.no/ongoing-prospectuses-and-offerings/) og Arctic Securities AS
(www.arctic.com/secno/en/offerings). Ved å fylle ut og sende inn en
Utøvelsesblankett, forplikter innehaveren av Frittstående Tegningsretter seg til
å tegne et antall Nye Aksjer tilsvarende det antall Frittstående Tegningsretter
som utøves til den relevante utøvelsesprisen.

Selskapets primærinnsidere som er innehavere av Frittstående Tegningsretter har
indikert at de vil utøve alle sine respektive Frittstående Tegningsretter i den
første utøvelsesperioden.

Betaling for, og levering av, Nye Aksjer

Melding om allokerte Nye Aksjer og den korresponderende samlede utøvelsesprisen
som skal betales av hver tegner forventes å bli distribuert i et brev fra VPS
etter utløpet av den første utøvelsesperioden på eller rundt 30. november 2023.
Betaling for de Nye Aksjene tildelt til tegneren etter utløpet av den første
utøvelsesperioden forfaller til betaling 5. desember 2023 i samsvar med
betalingsprosedyrene beskrevet i Utøvelsesblanketten.

Forutsatt rettidig betaling av tegningsbeløpet for de Nye Aksjene den 5.
desember 2023, forventer Selskapet at aksjekapitalforhøyelsen knyttet til
utøvelse av Frittstående Tegningsretter vil bli registrert i Foretaksregisteret
på eller rundt 6. desember 2023 og at de Nye Aksjene vil bli levert til VPS
-kontiene til de tegnerne som de tildeles på eller rundt 7. desember 2023.

De Nye Aksjene kan ikke overføres eller handles før de er fullt betalt og
aksjekapitalforhøyelsen knyttet til utøvelse av Frittstående Tegningsretter
registreres i Foretaksregisteret.

En tegners mislighold av rettidig betaling av utøvelsesbeløpet for de Nye
Aksjene som tegnes av slik tegner vil resultere i at de Nye Aksjene ikke vil bli
utstedt og at de Frittstående Tegningsrettene som er utøvet vil bli tapt og vil
ikke gi rett til å tegne Nye Aksjer.

Finansielle mellommenn

Dersom Frittstående Tegningsretter er registrert gjennom en finansiell
mellommann, vil den finansielle mellommannen vanligvis gi innehaveren detaljer
om det samlede antall Frittstående Tegningsretter som innehaveren er berettiget
til å utøve. Den relevante finansielle mellommannen vil vanligvis gi denne
informasjonen som ledd i dens vanlige kundekontaktprosedyrer. Innehavere av
Frittstående Tegningsretter gjennom en finansiell mellommann bør kontakte den
finansielle mellommannen dersom de ikke har mottatt noen informasjon vedrørende
de Frittstående Tegningsrettene.

Notering og start av handel i de Nye Aksjene

De Nye Aksjene som utstedes ved utøvelse av Frittstående Tegningsretter vil bli
notert på Oslo Børs under ISIN NO 001 0650013 og ticker-kode “BGBIO”. De Nye
Aksjene vil bli notert så snart de Nye Aksjene er fullt betalt,
aksjekapitalforhøyelsen knyttet til de Nye Aksjene er registrert i
Foretaksregisteret, de Nye Aksjene er utstedt i VPS og Selskapet har publisert
et prospekt knyttet til notering av de Nye Aksjene godkjent av Finanstilsynet
(“Noteringsprospektet”).

De Nye Aksjene vil, om nødvendig, bli plassert på en separat ISIN i påvente av
publisering av Noteringsprospektet inntil de noteres. Noteringsprospektet vil
bli publisert på Selskapets nettside så snart det har blitt godkjent av
Finanstilsynet, hvilket forventes å være på eller rundt 7. desember 2023.

De Nye Aksjene forventes å kunne handles på Oslo Børs fra det tidspunkt
Selskapet har publisert Noteringsprospektet godkjent av Finanstilsynet.

For ytterligere informasjon, vennligst kontakt:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

For informasjon om de Frittstående Tegningsrettene, vennligst kontakt en av
Tilretteleggerne::

Arctic Securities AS, tlf.: + 47 21 01 30 40

Carnegie AS, tlf.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is published in accordance with the requirements of the
Continuing Obligations.

Kilde

[E24Bot]

Bergenbios aksjonærer står i en hyggelig valgsituasjon

Bergenbios aksjonærer står i en hyggelig valgsituasjon

[TekBot]

BerGenBio ASA Mandatory notification of trade by primary insiders and close associates

Bergen 21 November 2023 - Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 15 June 2023 regarding the
allocation of offer shares and warrants (the “Warrants”) to certain primary
…

Vis børsmeldingen

insiders and close associates of primary insiders of the Company in connection
with the June 2023 rights issue completed pursuant to a resolution by the
Company’s annual general meeting on 22 May 2023. Reference is further made to
the Company’s stock exchange announcement published on 15 November 2023
regarding the commencement of the first exercise period for the Warrants. Each
Warrant gives the holder a right to subscribe for one new share (“New Share”) in
the Company. The Warrants are listed and tradable on the Oslo Stock Exchange
until 16:30 hours (CEST) on 8 April 2024 under the ticker code “BGBIS”.

Today, the Company has been informed that the following primary insiders and
close associate has exercised all their respective Warrants on 20 November 2023:

· Martin Olin (CEO): 1,000,000 Warrants, for the allocation of 1,000,000 New
Shares in the Company at a price per New Share of NOK 0.13.
· Rune Skeie (CFO): 129,595 Warrants, for the allocation of 129,595 New Shares
in the Company at a price per New Share of NOK 0.13.
· Anders Tullgren (chairman): 704,910 Warrants, for the allocation of 704,910
New Shares in the Company at a price per New Share of NOK 0.13.
· Sally Bennett (board member): 157,413 Warrants, for the allocation of
157,413 New Shares in the Company at a price per New Share of NOK 0.13.
· Debra Barker (board member): 155,513 Warrants, for the allocation of 155,513
New Shares in the Company at a price per New Share of NOK 0.13.
· Svev AS (company wholly owned by board member Sveinung Hole): 1,000,000
Warrants, for the allocation of 1,000,000 New Shares in the Company at a price
per New Share of NOK 0.13.

Please see further details about the transactions in the attached forms.

The New Shares issued upon exercise of Warrants will be listed on the Oslo Stock
Exchange under ISIN NO 001 0650013 and ticker code “BGBIO”. The New Shares will
be listed as soon as the New Shares have been registered in the VPS and the
Company has published a prospectus in relation to the listing of the New Shares,
approved by the Norwegian Financial Supervisory Authority (the “NFSA”).

The New Shares may not be transferred or traded before they are fully paid, and
the New Shares will, if required, be placed on a separate ISIN pending approval
and publication of the listing prospectus for the New Shares.

Subject to timely payment of the subscription price for the New Shares on 4
December 2023, the Company expects the share capital increase pertaining to the
exercise of Warrants to be registered with the Norwegian Register of Business
Enterprises on or about 6 December 2023 and that the New Shares will be
delivered to the VPS accounts of the subscribers to whom they are allocated on
or about 7 December 2023.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

Kilde

[Graziano]

Noen som hiver seg på og benytter seg av kjøp på 0,13? Virker jo som en god ting, uten at jeg har tenkt for mye rundt det.

[TekBot]

BerGenBio ASA - Information about the first exercise period for warrants issued in connection with rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF
THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH
…

Vis børsmeldingen

THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE
APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE
ANNOUNCEMENT.

Bergen 24 November 2023 - Reference is made to the stock exchange announcement
from BerGenBio ASA (the “Company”) dated 15 November 2023 regarding the
commencement of the first exercise period for the warrants issued in connection
with the rights issue in June 2023.

Information about the first warrants exercise period, 15 - 28 November 2023,
including a Q&A section is available on the Company’s website:

Warrants - BerGenBio

A Norwegian translation is available at the Company’s website:

Om tegningsrettene (Warrants) - BerGenBio

The first exercise period for the Warrants ends 28 November 2023 at 4:30 pm CET.

Carnegie AS and Arctic Securities AS are acting as managers in connection with
exercise of Warrants (jointly the “Managers”).

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

For information about the Warrants please contact one of the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is published in accordance with the requirements of the
Continuing Obligations.

Kilde

[TekBot]

BerGenBio ASA - Siste dag av den første utøvelsesperioden for de frittstående tegningsrettene utstedt i forbindelse med fortrinnsrettsemisjonen

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 28. november 2023 - Det vises til børsmeldingen fra BerGenBio ASA
(“Selskapet”) datert 15. november 2023 vedrørende start av den første
utøvelsesperioden for de 1.249.999.617 frittstående tegningsrettene (de
“Frittstående Tegningsrettene”) utstedt i forbindelse med
fortrinnsrettsemisjonen som reiste bruttoproveny på NOK 250 millioner
(“Fortrinnsrettsemisjonen”). De Frittstående Tegningsrettene er noterte fra 23.
juni 2023 og kan handles på Oslo Børs frem til kl 16:30 (CEST) den 8. april 2024
under ticker-koden “BGBIS”. Hver Frittstående Tegningsrett gir innehaveren rett
til å tegne en ny aksje i Selskapet i løpet av to utøvelsesperioder (slike nye
aksjer omtales samlet som “Nye Aksjene”).

Den første utøvelsesperioden for de Frittstående Tegningsrettene avsluttes i
dag, den 28. November 2023 kl. 16.30 (CET).

Frittstående Tegningsretter utøves ved innsendelse av en korrekt utfylt
utøvelsesblankett (“Utøvelsesblanketten”) til en av Arctic Securities AS eller
Carnegie AS (i fellesskap, “Tilretteleggerne”) på adressen eller e-postadressen
angitt i prospektet utarbeidet i forbindelse med Fortrinnsrettsemisjonen datert
26. mai 2023 (“Prospektet”) eller i Utøvelsesblanketten, eller elektronisk
gjennom VPS’ online tegningssystem i løpet av en av utøvelsesperiodene for de
Frittstående Tegningsrettene. Utøvelsesblanketten og link til VPS elektronisk
tegningssystem kan finnes på nettsidene til Selskapet
(Om tegningsrettene (Warrants) - BerGenBio),
Carnegie AS (www.carnegie.no/ongoing-prospectuses-and-offerings/) og Arctic
Securities AS (www.arctic.com/secno/en/offerings). Ved å fylle ut og sende inn
en Utøvelsesblankett eller tegne elektronisk via VPS, forplikter innehaveren av
Frittstående Tegningsretter seg til å tegne et antall Nye Aksjer tilsvarende det
antall Frittstående Tegningsretter som utøves til den relevante utøvelsesprisen.

For ytterligere informasjon, vennligst kontakt:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

For informasjon om de Frittstående Tegningsrettene, vennligst kontakt en av
Tilretteleggerne::

Arctic Securities AS, tlf.: + 47 21 01 30 40

Carnegie AS, tlf.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is published in accordance with the requirements of the
Continuing Obligations.

Kilde

[TekBot]

BerGenBio ASA - Last day of the first exercise period for warrants issued in connection with rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 28 November 2023 - Reference is made to the stock exchange announcement
from BerGenBio ASA (the “Company”) dated 15 November 2023 regarding the
commencement of the first exercise period for the 1,249,999,617 warrants
(“Warrants”) issued in connection with the rights issue raising gross proceeds
of NOK 250 million (the “Rights Issue”). The Warrants are listed and tradable on
the Oslo Stock Exchange from 23 June 2023 to 16:30 hours (CEST) on 8 April 2024
under the ticker code “BGBIS”. Each Warrant gives the holder a right to
subscribe for one new share in the Company during two exercise periods (such new
shares jointly the “New Shares”).

The first exercise period for the Warrants expires today, on 28 November 2023 at
16:30 (CET).

Warrants are exercised through the submission of a duly completed exercise form
for the Warrants (the “Exercise Form”) to Arctic Securities AS or Carnegie AS
(acting as managers, the “Managers”) at the address or email address set out in
the prospectus prepared in connection with the Rights Issue dated 26 May 2023
(the “Prospectus”), and in the Exercise Form, or electronically through the VPS
online subscription system, during one of the exercise periods for the Warrants.
The Exercise Form and link to VPS online subscription system can be found at the
websites of the Company (https://www.bergenbio.com/investors/investor
-relations/warrants), Carnegie AS (www.carnegie.no/ongoing-prospectuses-and
-offerings/) and Arctic Securities AS (www.arctic.com/secno/en/offerings). By
completing and submitting an Exercise Form or completing the VPS online
subscription, the holder of the relevant Warrants irrevocably undertakes to
acquire a number New Shares equal to the number of Warrants exercised at the
relevant exercise price.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

For information about the Warrants please contact one of the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is published in accordance with the requirements of the
Continuing Obligations.

Kilde

[TekBot]

BerGenBio ASA - Preliminary results for the first exercise period for warrants issued in connection with rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH
…

Vis børsmeldingen

THEDISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 29 November 2023 - Reference is made to the stock exchange announcement
from BerGenBio ASA (the “Company”) on 28 November 2023 regarding the last day of
the first exercise period for the 1,249,999,617 warrants (the “Warrants”) issued
in connection with the rights issue raising gross proceeds of NOK 250 million
(the “Rights Issue”).

The first exercise period for the Warrants expired at 16:30 hours (CET)
yesterday, on 28 November 2023.

Preliminary results indicates that 67,157,682 Warrants were exercised in the
first exercise period, resulting in an aggregate allocation of 67,157,682 new
shares in the Company (the “New Shares”) at a subscription price of NOK 0.13 per
New Share to those who exercised Warrants in the first exercise period, raising
gross proceeds of approximately NOK 8.7 million.

The final result of allocation of New Shares is expected to be published
tomorrow, 30 November 2023, and notification of allocated New Shares and the
corresponding aggregate exercise price to be paid by each subscriber, are
expected to be distributed in a letter from the VPS tomorrow, 30 November 2023.

The due date for payment of the New Shares is 5 December 2023.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

For information about the Warrants please contact one of the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Rune Skeie, CFO at BerGenBio
ASA on 29 November 2023 at 19:00 hours (CET) on behalf of the Company.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

Kilde

[TekBot]

BerGenBio ASA - Final results for the first exercise period for warrants issued in connection with rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 30 November 2023 - Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 29 November 2023 regarding the
preliminary results for the first exercise period for the 1,249,999,617 warrants
(the “Warrants”) issued in connection with the rights issue raising gross
proceeds of NOK 250 million (the “Rights Issue”).

The first exercise period for the Warrants expired at 16:30 hours (CET) on 28
November 2023. At the expiry of the first exercise period, 68,156,682 Warrants
were exercised, resulting in an aggregate subscription of 68,156,682 new shares
in the Company (“New Shares”) to the subscribers at a subscription price of NOK
0.13 per New Share, raising gross proceeds of approximately NOK 8.9 million.

The final allocation of the New Shares has now been completed resulting in the
Company allocating a total of 68,156,682 New Shares to investors holding
Warrants.

Notifications of allocated New Shares and the corresponding aggregate exercise
price to be paid by each subscriber are expected to be distributed today, on 29
November 2023.

Payment for the allocated New Shares falls due on 5 December 2023.

The New Shares may not be transferred or traded before (i) they have been fully
paid, (ii) the share capital increase pertaining to the New Shares has been
registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret), (iii) the New Shares have been issued in the VPS, and (iv)
the Company has published a prospectus in relation to the listing of the New
Shares approved by the Norwegian Financial Supervisory Authority (the “NFSA”)
(the “Listing Prospectus”).

The New Shares will, if required, be placed on a separate ISIN pending
publication of the Listing Prospectus until they are listed. The Listing
Prospectus will be published on the Company’s web site once it has been approved
by the NFSA, which is expected to be on or about 7 December 2023.

The New Shares are expected to be tradable on the Oslo Stock Exchange from the
time the Company has published the Listing Prospectus approved by the NFSA.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

For information about the Warrants please contact one of the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Rune Skeie, CFO at BerGenBio
ASA on 30 November 2023 at 17:30 hours (CET) on behalf of the Company.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

Kilde

[TekBot]

BerGenBio ASA - Updated timeline for delivery of new shares

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 7 December 2023 - Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 15 November 2023 regarding the
commencement of the first exercise period for the 1,249,999,617 warrants (the
“Warrants”) issued in connection with the rights issue raising gross proceeds of
NOK 250 million (the “Rights Issue”).

Reference is further made to the stock exchange announcement published by the
Company on 30 November 2023 regarding the final results for the first exercise
period for Warrants, resulting in an aggregate subscription and allocation of
68,156,682 new shares in the Company (“New Shares”) to the subscribers.

Full payment for all New Shares was received a day later than the due date, on 6
December 2023, due to lack of sufficient funds on certain subscriber’s
designated bank accounts. The New Shares may not be transferred or traded before
the share capital increase pertaining to the New Shares has been registered with
the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret).

We will publish a new stock exchange announcement once the share capital
increase pertaining to the New Shares has been registered with the Norwegian
Register of Business Enterprises (Nw. Foretaksregisteret).

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

For information about the Warrants please contact one of the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is published in accordance with the requirements of the
Continuing Obligations.

Kilde

[TekBot]

BerGenBio ASA: Approval and publication of prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA,
JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES
…

Vis børsmeldingen

NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE
THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Bergen 7 December 2023 - Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 30 November 2023 regarding the
final results for the first exercise period for the 1,249,999,617 warrants (the
“Warrants”) issued in connection with the rights issue raising gross proceeds of
NOK 250 million (the “Rights Issue”). Each Warrant gives the holder a right to
subscribe for one new share in the Company during two exercise periods (such new
shares jointly the “New Shares”).

The Financial Supervisory Authority of Norway (Nw: Finanstilsynet) has today, on
7 December 2023, approved a prospectus prepared by the Company in connection
with the listing of the New Shares (the “Prospectus”). Subject to local
applicable securities laws, the Prospectus will be made available at the
websites of the Company in the Investor section
(Warrants - BerGenBio). The
Prospectus has been prepared for the purpose of listing the New Shares only.
Consequently, no securities are being offered under the Prospectus.

68,156,682 of the New Shares which were subscribed for in the first exercise
period are expected to be tradable on the Oslo Stock Exchange from the time the
share capital increase pertaining to such new shares have been registered with
the Norwegian Register of Business Enterprises.

Advisers: Carnegie AS and Arctic Securites AS (the “Managers”) have been
retained by the Company to act as managers, and Advokatfirmaet Thommessen AS is
acting as legal adviser to the Company, in connection with the first exercise
period for the Warrants.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the
“U.S.Securities Act”). The securities of the Company have not been, and will not
be, registered under the U.S. Securities Act. Any sale in the United States of
the

securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is

available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking

statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the Prospectus dated 26 May 2023 and stock exchange announcements published in
connection with the Rights Issue and the Warrants. Copies of the Prospectus is
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Company (www.bergenbio.com), (Carnegie
www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities
AS(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is published in accordance with the requirements of the
Continuing Obligations.

Kilde

[TekBot]

BerGenBio ASA - New share capital registered

Bergen 8 December 2023 - Reference is made to the stock exchange announcement by
BerGenBio ASA (the “Company”) on 30 November 2023 regarding the final results of
the first exercise period for the warrants (“Warrants”) issued in connection
…

Vis børsmeldingen

with the rights issue, which resulted in an allocation of 68,156,682 new shares
in the Company (“New Shares”) to investors holding Warrants.

The share capital increase pertaining to the New Shares is now registered with
the Norwegian Register of Business Enterprises. After this, the Company’s new
registered share capital is NOK 268,868,921.40 divided into 2,688,689,214
shares, each with a nominal value of NOK 0.10.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA: Grant of share options

Bergen, Norway, 8 December 2023 - BerGenBio ASA (the “Company”) (OSE:BGBIO), a
clinical-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical needs, today announce that the Board of
…

Vis børsmeldingen

Directors has granted options to employees.

The annual general meeting in the Company on 22 May 2023 approved the share
option program and authorised the board of directors of the Company to issue up
to 129,090,000 share options to the Company’s employees as part of a long-term
incentive plan.

Options granted under the share option program will normally vest equally over a
three-year period from the date of grant and each option, when exercised, will
give the right to receive one share in the Company at a fixed strike price set
at time of grant. Options granted under the share option program expire eight
years after grant date.

A total of 112,000,000 share options were granted, equal to 4.2% of total issued
shares in the Company and 2.8% on a fully dilutive basis including all
outstanding Warrants and options. The strike price for this grant is NOK 0.2113
per option equal to the volume weighted average share price the last 14 days
before the grant.

The board considers an option program as an important element in attracting and
retaining employees to foster long-term success. The board considers the option
program terms and allocation to be at the market for comparable peers.

After this grant total issued options equals 4.3% of the total issued shares in
the Company and 2.9% on a fully dilutive basis compared to the average level
over the last five years of 5.5% of issued shares in the Company and 5.0% on a
fully dilutive basis.

Of the total grant the following were granted to primary insiders (total
holdings of share options following this grant):

Martin Olin - CEO: 24,000,000 (24,950,000)

Rune Skeie - CFO: 12,000,000 (12,397,097)

Cristina Oliva - CMO: 12,000,000 (12,200,000)

In total 48,000,000 share options were granted to primary insiders.

Following this grant a total of 115,586,772 share options are issued, equal to
4.3% of the total shares issued in the Company. Of this, 2,228,807 share options
are vested and 113,357,965 not vested.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[LarsErik64]

Dette er ikke akkurat et dårlig tegn for å si det sånn

[BillyP]

The strike price for this grant is NOK 0.2113
per option equal to the volume weighted average share price the last 14 days
before the grant.

[Hotdog]

Etter Skeie sin opptreden på finansavisen TV for noe måneder siden så MÅ det være veldig viktig å gi han 12 mill opsjoner.

[urban66]

Apropos fuzz om opsjoner. Alle og enhver kan jo kjøpe 12 mill aksjer på mandag, til akkurat samme pris Skeie må betale for å realisere sine opsjoner.

[Hotdog]

Alle kan kjøpe aksjer på mandag til 21 øre men Skeie kan vente til aksjen feks stiger til 2 kr og da fremdeles kjøpe aksjer til 21 øre. Og synker aksjen til feks 5 øre så mister han bare de gratis mottatte opsjonene.

[LarsErik64]

Det er jonseptet med opsjoner ja, og han vil i så fall gevinstbeskattes på differansen mellom 0,21 til 2,00 med de samme prosentsatser som deg og meg. Det skulle vel bli sånn ca. 41%, subsidiært ca 9 mill i skatt av gevinst på opsjonen.

Ansatte vil ha tilgang til opsjoner slik det er i alle bedrifter, jeg finner tidspunktet mer interessant sett i relasjon til progresjonen i utvikling av produkter i BergenBio. Slik jeg leser dette så virker dette positivt i mine øyne da innsidehandel er utelukket om det er progresjon i partnerdialog.

Kun mine personlige meninger, og ikke aksjeråd. Korriger meg gjerne om det er noen feil i “matematikken”